Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(4):221; doi:10.1093/jnci/djj082
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Redox Modulators and Anticancer Drug Activity

Mangafodipir, a contrast agent used in magnetic resonance imaging, modifies the production of reactive oxygen species in ways that could prove useful for cancer therapy. As a superoxide dismutase mimic, it catalyzes the production of hydrogen peroxide, which is toxic to cancer cells. Via its catalase and glutathione reductase activities it can protect normal cells from death induced by reactive oxygen species, whose intracellular levels increase after treatment with anticancer drugs. In this issue (p. 236), Alexandre et al. examined the effect of mangafodipir on anticancer drug activity and cytotoxicity against both normal and cancer cells. Mangafodipir protected . . . [Full Text of this Article]

Antioxidant Vitamins and Prostate Cancer Risk

Gene Methylation in Tumor-Associated Normal Cells

Breast Cancer Grade and Gene Expression Profiling

Darbepoetin Alfa Treatment Every 3 Weeks

MDM2 SNP, p53 Status, and Colorectal Cancer Onset


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?